126 related articles for article (PubMed ID: 10537142)
21. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
[TBL] [Abstract][Full Text] [Related]
22. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.
Virgolini I; Leimer M; Handmaker H; Lastoria S; Bischof C; Muto P; Pangerl T; Gludovacz D; Peck-Radosavljevic M; Lister-James J; Hamilton G; Kaserer K; Valent P; Dean R
Cancer Res; 1998 May; 58(9):1850-9. PubMed ID: 9581824
[TBL] [Abstract][Full Text] [Related]
24. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines.
Vilner BJ; John CS; Bowen WD
Cancer Res; 1995 Jan; 55(2):408-13. PubMed ID: 7812973
[TBL] [Abstract][Full Text] [Related]
25. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
26. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
27. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
[TBL] [Abstract][Full Text] [Related]
28. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
Virgolini I; Britton K; Buscombe J; Moncayo R; Paganelli G; Riva P
Semin Nucl Med; 2002 Apr; 32(2):148-55. PubMed ID: 11965610
[TBL] [Abstract][Full Text] [Related]
29. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and binding properties of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues.
Tran TA; Mattern RH; Morgan BA; Taylor JE; Goodman M
J Pept Sci; 1999 Mar; 5(3):113-30. PubMed ID: 10323556
[TBL] [Abstract][Full Text] [Related]
31. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro evaluation of an 111In-labeled ST-peptide enterotoxin (ST) analogue for specific targeting of guanylin receptors on human colonic cancers.
Gali H; Sieckman GL; Hoffman TJ; Kiefer GE; Chin DT; Forte LR; Volkert WA
Anticancer Res; 2001; 21(4A):2785-92. PubMed ID: 11724355
[TBL] [Abstract][Full Text] [Related]
33. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism.
Viguerie N; Tahiri-Jouti N; Ayral AM; Cambillau C; Scemama JL; Bastié MJ; Knuhtsen S; Estève JP; Pradayrol L; Susini C
Endocrinology; 1989 Feb; 124(2):1017-25. PubMed ID: 2563240
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma.
Vuaroqueaux V; Dutour A; Bourhim N; Ouafik L; Monges G; Briard N; Sauze N; Oliver C; Grino M
J Mol Endocrinol; 2000 Jun; 24(3):397-408. PubMed ID: 10828833
[TBL] [Abstract][Full Text] [Related]
35. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
36. Receptor targeting for tumor localisation and therapy with radiopeptides.
Heppeler A; Froidevaux S; Eberle AN; Maecke HR
Curr Med Chem; 2000 Sep; 7(9):971-94. PubMed ID: 10911025
[TBL] [Abstract][Full Text] [Related]
37. Iodination of [Tyr11]somatostatin yields a super high affinity ligand for somatostatin receptors in GH4C1 pituitary cells.
Presky DH; Schonbrunn A
Mol Pharmacol; 1988 Nov; 34(5):651-8. PubMed ID: 2904115
[TBL] [Abstract][Full Text] [Related]
38. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
Stolz B; Weckbecker G; Smith-Jones PM; Albert R; Raulf F; Bruns C
Eur J Nucl Med; 1998 Jul; 25(7):668-74. PubMed ID: 9662587
[TBL] [Abstract][Full Text] [Related]
39. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
